Optimized zein nanospheres for improved oral bioavailability of atorvastatin

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4059-4069

  Hashem, Fahima M ^a   Al Sawahli, Majid M ^b   Nasr, Mohamed ^a   Ahmed, Osama A A ^c,d  

^a HELWAN UNIVERSITY   (Egypt)

^b Holding Company for Biological Products and Vaccines   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d MINIA UNIVERSITY   (Egypt)

Author keywords

Experimental design; Fractional factorial design; Nanoparticles; Optimization

Indexed keywords

ATORVASTATIN; NANOSPHERE; ZEIN; DRUG CARRIER;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ENCAPSULATION; DRUG FORMULATION; DRUG LOADING; DRUG RELEASE; DRUG SOLUBILITY; DRUG YIELD; EXCIPIENT COMPATIBILITY; FACTORIAL DESIGN; FEMALE; LIQUID LIQUID PHASE SEPARATION; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PH; PHARMACOLOGICAL PARAMETERS; PHASE SEPARATION; RAT; STIRRING TIME; WEIGHT; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; WISTAR RAT;

RATTUS;

ANIMALS; ATORVASTATIN CALCIUM; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; NANOSPHERES; RATS; RATS, WISTAR; ZEIN;

EID: 84933566486     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S83906     Document Type: Article

References (33)

1. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995;31:9–27.
2. Igel M, Sudhop T, Von BK. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002;42:835–845.
3. Breitkreitz MC, Sabin GP, Polla G, Poppi RJ. Characterization of semi-solid self-emulsifying drug delivery systems (SEDDS) of atorvastatin calcium by Raman image spectroscopy and chemometrics. J Pharm Biomed Anal. 2013;73:3–12.
4. Shete G, Puri V, Kumar L, Bansal AK. Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS Pharm Sci Tech. 2010;11:598–609.
5. Ronaldson KJ, O’Shea JM, Boyd I W. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf. 2006;29:1061–1067.
6. Zhong Q, Jin M. Nanoscalar structures of spray-dried zein microcap-sules and in vitro release kinetics of the encapsulated lysozyme as affected by formulations. J Agric Food Chem. 2009;57:3886–3894.
7. Ahmed OA, Hosny KM, Al-Sawahli MM, Fahmy UA. Optimization of caseinate coated simvastatin-zein nanoparticles: improved bioavail-ability and modified release characteristics. Drug Des Devel Ther. 2015;9:655–662.
8. Shukla R, Cheryan M. Zein: the industrial protein from corn. Ind Crops Prod. 2001;13:171–192.
9. Meena AK, Ratnam DV, Chandraiah G, Ankola DD, Rao PR, Kumar MN. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia. Lipids. 2008;43:231–241.
10. Desai DP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations. Drug Discov Today Technol. 2012;9:87–95.
11. Liu X, Sun Q, Wang H, Zhang L, Wang J Y. Microspheres of corn protein, zein, for an ivermectin drug delivery system. Biomaterials. 2005;26: 109–115.
12. Lai LF, Guo HX. Preparation of new 5-fuorouracil-loaded zein nano-particles for liver targeting. Int J Pharm. 2011;404:317–323.
13. Lai LF, Guo HX. Preparation of new 5-fuorouracil-loaded zein nano-particles for liver targeting. Int J Pharm. 2011;404:317–323.
14. Lee JH, Park TG, Lee YB, Shin SC, Choi HK. Effect of adding nonvolatile oil as a core material for the foating microspheres prepared by emulsion solvent diffusion method. J Microencapsul. 2001;18: 65–75.
15. Chen L, Hebrard G, Beyssac E, Denis S, Subirade M. In vitro study of the release properties of soy-zein protein microspheres with a dynamic artificial digestive system. J Agric Food Chem. 2010;58:9861–9867.
16. Podaralla S, Perumal O. Preparation of zein nanoparticles by pH controlled nanoprecipitation. J Biomed Nanotechnol. 2010;6:312–317.
17. Suzuki T, Sato E, Matsuda Y, Tada H, Unno K, Kato T. Preparation of zein microspheres conjugated with antitumor drugs available for selective cancer chemotherapy and development of a simple colorimetric determination of drugs in microspheres. Chem Pharm Bull (Tokyo). 1989;37:1051–1054.
18. Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Microniza-tion of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009;374:106–113.
19. Sah H, Toddywala R, Chien Y W. The infuence of biodegradable micro-capsule formulations on the controlled release of a protein. J Control Release. 1994;30:201–211.
20. Stanisz B, Kania L. Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase. Acta Pol Pharm. 2006;4:476–471.
21. O’Hagan DT, Jeffery H, Davis SS. The preparation and characterization of PLGA microspheres: III. Microparticle/polymer degradation rates and the in vitro release of a model protein. Int J Pharm. 1994;103:37–45.
22. Ye o Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27:1–12.
23. Shum YY, Huang N, Walter G, et al. Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit. 1998;20:41–49.
24. Zhang Y, Niu Y, Luo Y et al. Fabrication, characterization and antimicrobial activities of thymol-loaded zein nanoparticles stabilized by sodium caseinate-chitosan hydrochloride double layers. Food Chem. 2014;142:269–275.
25. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multi-drug resistance in cancer. Mol Pharm. 2010;7:863–869.
26. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615–627.
27. Kumar V, Hong SY, Maciag AE, et al. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles. Mol Pharm. 2010;7: 291–298.
28. Liversidge GG, Cundy KC. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs:1. Absolute oral bio-availability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91–97.
29. Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension. Int J Pharm. 2014;478:540–552.
30. Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using fractional factorial design. Daru. 2010;18:1–8.
31. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphot-ericin B. Nanomedicine. 2011;2:242–247.
32. Du S, Zhu L, Du B, et al. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev Ind Pharm. 2012;38:431–438.
33. Hurtado-Lopez P, Murdan S. Zein microspheres as drug/antigen carriers: a study of their degradation and erosion, in the presence and absence of enzymes. J Microencapsul. 2006;23:303–314.